Page 49 - Alpine Immune Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Interview with Jay Venkatesan, M.D., the President, Chief Executive Officer, and Chairman of Angion Biomedica Corp. (ANGN).

Zacks Investment Research cut shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the […]

Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings. Alpine Immune Sciences posted earnings per share of ($0.45) in the same quarter last year, which would indicate a positive […]

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23), MarketWatch Earnings reports. Alpine Immune Sciences had a negative return on equity of 58.85% and a negative net margin of 169.03%. Shares […]

News, features, and commentary about cancer-related issues